dc.contributor.author | Coşar, Begüm | |
dc.contributor.author | Karagülleoğlu, Zeynep Yağmur | |
dc.contributor.author | Ünal, Sinan | |
dc.contributor.author | İnce, Ahmet Turan | |
dc.contributor.author | Uncuoğlu, Dilruba Beyza | |
dc.contributor.author | Tuncer, Gizem | |
dc.contributor.author | Kılınç, Buğrahan Regaip | |
dc.contributor.author | Özkan, Yunus Emre | |
dc.contributor.author | Özkoç, Hikmet Ceyda | |
dc.contributor.author | Demir, İbrahim Naki | |
dc.contributor.author | Eker, Ali | |
dc.contributor.author | Karagöz, Feyzanur | |
dc.contributor.author | Şimsek, Said Yasin | |
dc.contributor.author | Yaşar, Bünyamin | |
dc.contributor.author | Pala, Mehmetcan | |
dc.contributor.author | Demir, Ayşegül | |
dc.contributor.author | Atak, İrem Naz | |
dc.contributor.author | Mendi, Ayşegül Hanife | |
dc.contributor.author | Bengi, Vehdi Umut | |
dc.contributor.author | Sevel, Güldane Cengiz | |
dc.contributor.author | Altuntaş, Evrim Güneş | |
dc.contributor.author | Kılıç, Pelin | |
dc.contributor.author | Demir Dora, Devrim | |
dc.date.accessioned | 2022-09-12T10:36:47Z | |
dc.date.available | 2022-09-12T10:36:47Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12868/1574 | |
dc.description.abstract | Mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occur spontaneously during
replication. Thousands of mutations have accumulated and continue to since the emergence of the virus. As novel
mutations continue appearing at the scene, naturally, new variants are increasingly observed.
Since the first occurrence of the SARS-CoV-2 infection, a wide variety of drug compounds affecting the binding
sites of the virus have begun to be studied. As the drug and vaccine trials are continuing, it is of utmost
importance to take into consideration the SARS-CoV-2 mutations and their respective frequencies since these
data could lead the way to multi-drug combinations. The lack of effective therapeutic and preventive strategies
against human coronaviruses (hCoVs) necessitates research that is of interest to the clinical applications.
The reason why the mutations in glycoprotein S lead to vaccine escape is related to the location of the mutation and the affinity of the protein. At the same time, it can be said that variations should occur in areas such as
the receptor-binding domain (RBD), and vaccines and antiviral drugs should be formulated by targeting more
than one viral protein. | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.cytogfr.2021.06.001 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | COVID-19 Mutation Receptor-binding domain SARS-CoV-2 Spike protein Viral variants | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Mutation | en_US |
dc.subject | Receptor binding domain | en_US |
dc.subject | Spike protein | en_US |
dc.subject | Viral variants | en_US |
dc.title | SARS-CoV-2 mutations and their viral variants | en_US |
dc.type | article | en_US |
dc.contributor.department | ALKÜ, Enstitüler, Lisansüstü Eğitim Enstitüsü, Moleküler Tıp Ana Bilim Dalı | en_US |
dc.identifier.volume | 63 | en_US |
dc.identifier.startpage | 10 | en_US |
dc.identifier.endpage | 22 | en_US |
dc.relation.journal | Cytokine & Growth Factor Reviews | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - İdari Personel ve Öğrenci | en_US |